45th week of 2014 patent applcation highlights part 42 |
Patent application number | Title | Published |
20140329832 | METABOLIC DEGRADATION INHIBITORS FOR ANTI-HYPERPROLIFERATIVE AGENTS - The present invention provides methods of increasing an amount of a treatment agent in the body, a cancer or tumor. The methods include administering an inhibitor of the metabolic degradation or conversion of the treatment agent to a subject undergoing treatment for a hyperproliferative disorder with said treatment agent. Methods of treating hyperproliferative disorders, tumors and cancers are also provided. | 2014-11-06 |
20140329833 | LYSINE DEMETHYLASE INHIBITORS FOR INFLAMMATORY DISEASES OR CONDITIONS - The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases or conditions. | 2014-11-06 |
20140329834 | Small Molecule Inhibitors of Ebola and Lassa Fever Viruses - The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses. | 2014-11-06 |
20140329835 | DOSAGE FORM FOR INSERTION INTO THE MOUTH - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 2014-11-06 |
20140329836 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2014-11-06 |
20140329837 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE - Arylpyrazinone derivatives of formula (I), | 2014-11-06 |
20140329838 | SUBSTITUTED IMIDAZOPYRIMIDIN-5(6H)-ONES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-11-06 |
20140329839 | New Crystalline Form of Pemirolast - There is provided a hemihydrate form of the sodium salt of pemirolast. | 2014-11-06 |
20140329840 | MOLECULES WITH POTENT DHFR BINDING AFFINITY AND ANTIBACTERIAL ACTIVITY - 7-(substituted) derivatives of 7H-pyrrolo[3,2-f]-quinazoline-1,3-diamines, derivative thereof, and methods of using them are provided. The pharmaceutical formulations prepared from the compounds can be used to treat a variety of conditions, which include, but are not limited to bacterial and fungal infections. The compounds can also be used as a sterilizing or disinfecting agent. | 2014-11-06 |
20140329841 | Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia - Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations. | 2014-11-06 |
20140329842 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2014-11-06 |
20140329843 | HIGH DOSE BUPRENORPHINE COMPOSITIONS AND USE AS ANALGESIC - The present disclosure relates to a method of providing prolonged analgesia to a mammal in need thereof. Specifically, the current disclosure is directed to a method of treating pain in a mammal for a prolonged period of time using a single high dose of a buprenorphine formulation. | 2014-11-06 |
20140329844 | METHOD OF RESTORING THE INCRETIN EFFECT - The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof. | 2014-11-06 |
20140329846 | Morphinan Compounds - This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 2014-11-06 |
20140329847 | METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENT - The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment. | 2014-11-06 |
20140329848 | DEUTERATED AMLEXANOX - Provided herein is technology relating to deuterated amlexanox and particularly, but not exclusively, to compositions comprising deuterated amlexanox, methods of producing deuterated amlexanox, and uses of deuterated amlexanox. | 2014-11-06 |
20140329849 | HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE - The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease. | 2014-11-06 |
20140329850 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS - The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula | 2014-11-06 |
20140329851 | DEUTERIUM-ENRICHED PRASUGREL - The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2014-11-06 |
20140329852 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS - The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2014-11-06 |
20140329853 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions. | 2014-11-06 |
20140329854 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL IN SIRTUIN BINDING AND MODULATION - Provided are novel heterocyclic sirtuin binding agents, e.g., N-aryl substituted pyridine dicarboxamides, which are useful as sirtuin modulators. Also provided are methods of using the pyridine dicarboxamide compounds for treating sirtuin mediated disorders and conditions, such as diabetes, cancers, and obesity and diseases related to aging. | 2014-11-06 |
20140329855 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 2014-11-06 |
20140329856 | METHOD OF TREATING PAIN - The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain. | 2014-11-06 |
20140329857 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of the formula: | 2014-11-06 |
20140329858 | Cyclic Urea Derivatives As Androgen Receptor Antagonists - The present invention is directed to compounds of formula (I) wherein R | 2014-11-06 |
20140329859 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NEUTICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY - The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake. | 2014-11-06 |
20140329860 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES - Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein. | 2014-11-06 |
20140329861 | Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia - Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations. | 2014-11-06 |
20140329862 | Glucagon Receptor Modulators - The present invention provides a compound of Formula (I) | 2014-11-06 |
20140329863 | NOVEL ANTIPRION COMPOUNDS - Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease. | 2014-11-06 |
20140329864 | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid - The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). | 2014-11-06 |
20140329865 | Pesticidal Mixtures - The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein B | 2014-11-06 |
20140329866 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS - This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 2014-11-06 |
20140329867 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS - The present invention relates to use of inhibitors of Notch signalling pathway selected from the group consisting of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, in treating and/or preventing cancers. | 2014-11-06 |
20140329868 | METHODS FOR TREATING HYPERTENSION - The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 2014-11-06 |
20140329869 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS IN RESPONDERS - A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof comprising administering to said subject an effective amount of (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole or pharmaceutically acceptable salt thereof, wherein said subject is a treatment responder. In certain embodiments, said subject is a subject with definite amyotrophic lateral sclerosis, a subject with amyotrophic lateral sclerosis symptom onset duration of less than about 18 months, a subject with a high level of serum creatinine, a subject with concomitant riluzole administration and combinations thereof. | 2014-11-06 |
20140329870 | COMPOSITIONS COMPRISING ISOSORBIDE MONOESTERS AND ISOTHIAZOLINONES - What are described are compositions comprising
| 2014-11-06 |
20140329871 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF - The present invention provides compounds having the general structural Formula (I): | 2014-11-06 |
20140329872 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY - The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin. | 2014-11-06 |
20140329873 | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid - The meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. | 2014-11-06 |
20140329874 | ALPHA ADRENERGIC AGONISTS FOR THE TREATMENT OF TISSUE TRAUMA - The present invention provides a method of treating tissue trauma (such as damage from radiation (such as solar and ultraviolet radiation), wounds, bruising, burns, blisters, excoriations, incisions, excisions, and ulcers) in a subject, comprising topically administering to the tissue area of the subject affected by said trauma a composition comprising a therapeutically effective amount of at least one alpha adrenergic agonist (such as oxymetazoline hydrochloride). The present invention also provides a method for alleviating the pain or discomfort associated with aesthetic or plastic surgery or cosmetology procedures in a subject comprising administering said alpha adrenergic agonist. | 2014-11-06 |
20140329875 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FORTREATING DISEASE CONDITIONS, INCLUDING METABOLIC DISORDERS ANDCANCERS - The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 2014-11-06 |
20140329876 | PYRAZOLINE DERIVATIVES AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 2014-11-06 |
20140329877 | TRICYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF - Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith. | 2014-11-06 |
20140329878 | OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY - Disclosed herein are double stranded nucleic acid molecules and pharmaceutical compositions comprising same useful in the treatment of, inter alia, acute and chronic inflammation, neuropathic pain, primary graft dysfunction (PGD) after lung transplantation in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA compounds, which down regulate or inhibit expression of a Toll like receptor genes. | 2014-11-06 |
20140329879 | DIAGNOSIS AND TREATMENT OF TAXANE-RESISTANT CANCERS - Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof. | 2014-11-06 |
20140329880 | EXONUCLEASE RESISTANT POLYNUCLEOTIDE AND RELATED DUPLEX POLYNUCLEOTIDES, CONSTRUCTS, COMPOSITIONS, METHODS AND SYSTEMS - Provided herein are exonuclease resistant polynucleotides and related constructs, compositions, methods and systems. | 2014-11-06 |
20140329881 | EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY - Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described. | 2014-11-06 |
20140329882 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. | 2014-11-06 |
20140329883 | Pharmaceutical Composition Comprising Anti-miRNA Antisense Oligonucleotides - The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC. | 2014-11-06 |
20140329884 | 1,3,5-TRIAZINANE-2,4,6-TRIONE DERIVATIVES AND USES THEREOF - The present invention provides novel 1,3,5-triazinane-2,4,6-trione derivatives, such as compounds of any one of Formulae (I) and (II), and salts thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an siRNA, mRNA, or plasmid DNA). The present invention also provides methods and kits using the compositions for delivering an agent to a subject (e.g., to the liver, spleen, or lung of the subject) or cell and for treating and/or preventing a range of diseases, such as genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, and lung diseases. | 2014-11-06 |
20140329885 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), | 2014-11-06 |
20140329886 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING AMINO ACID BACKBONE - The invention provides a single-stranded nucleic acid molecule containing an expression inhibitory sequence that inhibits expression of a target gene, region (X), linker region (Lx), and region (Xc), wherein the linker region (Lx) is linked between the region (Xc) and the region (Xc), the region (Xc) is complementary to the region (X), at least one of the region (X) and the region (Xc) contains the expression inhibitory sequence, and the linker region (Lx) contains an atomic group derived from an amino acid. The single-stranded nucleic acid molecule can inhibit expression of the target gene. | 2014-11-06 |
20140329887 | MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY - Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer. | 2014-11-06 |
20140329888 | Compositions and Methods for the Intracellular Disruption of VEGF and VEGFR-2 by Intraceptors - The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors. | 2014-11-06 |
20140329889 | CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON - Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2′-5′ phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell. Also provided are compositions and kits for practicing the embodiments of the methods. | 2014-11-06 |
20140329890 | Compounds Having Anti-Adhesive Effects on Cancer Cells - Compounds of the form O-(x-L)n, where O is an oligonucleoside having at least a plurality of N3′→P5′ thiophosphoramidate (NPS) internucleoside linkages, a conjugated lipid moiety L, and at least one G-rich sequence motif as described, are effective to morphologically alter and reduce adhesion of cancer cells. | 2014-11-06 |
20140329891 | IN VITRO AND IN VIVO DELIVERY OF GENES AND PROTEINS USING THE BACTERIOPHAGE T4 DNA PACKAGING MACHINE - Described is T4 DNA packaging machine comprising: one or more DNA molecules packaged in a head of the T4 DNA packaging machine, one or more Hoc-fused proteins displayed on the head of the T4 DNA packaging machine, and one or more Soc-fused proteins displayed on the head of the T4 DNA packaging machine. Also described are methods of making and using such a T4 DNA packaging machine. | 2014-11-06 |
20140329892 | ADMINISTRATION OF A BIS(THIOHYDRAZIDE AMIDE) COMPOUND FOR TREATING CANCERS - Administration of a bis(thiohydrazide amide) compound is found to be surprisingly effective at treating subjects with cancer. Methods of treating a subject with cancer comprising continuously administering a bis(thiohydrazide amide) compound, or administering a bis(thiohydrazide amide) compound such that a constant concentration of the compound is achieved in the subject, are disclosed. | 2014-11-06 |
20140329893 | THERAPEUTIC COMPOSITIONS - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 2014-11-06 |
20140329894 | COMBINATION THERAPY AND USES THEREOF FOR TREATMENT AND PREVENTION OF PARASITIC INFECTION AND DISEASE - The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., | 2014-11-06 |
20140329895 | OLIGOMER-CANNABINOID CONJUGATES - The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds. | 2014-11-06 |
20140329896 | COMPOSITIONS AND METHODS OF TREATMENT WITH PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS - Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a | 2014-11-06 |
20140329897 | COMPOSITION FOR TREATING INFLUENZA A (H1N1) VIRUS AND A PREPARATION METHOD THEREFOR - New pharmaceutical compositions extracted from | 2014-11-06 |
20140329898 | Cosmetic Use of N-Substituted Sulfonyloxybenzylamines and Related Compounds - Cosmetic compositions comprising N-substituted sulfonyloxybenzylamines and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The N-substituted sulfonyloxybenzylamines are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging. | 2014-11-06 |
20140329899 | METHOD FOR PRODUCING SILVER-ION ANTIBACTERIAL LIQUID, SILVER-ION ANTIBATERIAL LIQUID PRODUCED BY SAID METHOD, METHOD FOR PRODUCING SILVER-ION ANTIBATERIAL POWDER, AND SILVER-ION ANTIBATERIAL POWDER PRODUCED BY SAID METHOD - A method for producing silver-ion antibacterial liquid using a type A or type X silver zeolite includes a process to weigh silver zeolite for obtain its blending quantity in a range of 0.1 to 20.0 percent by weight and to weigh citric acid for obtaining its blending quantity such that its blending ratio to the silver zeolite becomes 1.2 or greater, followed by blending of the two into purified water; a process to mix under agitation the silver zeolite and citric acid blended in the purified water to prepare a mixture liquid containing at least a citric acid-silver complex and silica hydrate; and a process to remove the silica hydrate produced in the mixture liquid. The production method can produce at low cost a silver-ion antibacterial liquid offering immediate bactericidal effect. | 2014-11-06 |
20140329900 | SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 2014-11-06 |
20140329901 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES - The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines. | 2014-11-06 |
20140329902 | LYSINE DELIVERY SYSTEMS FOR BLOOD COAGULATION - A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot. | 2014-11-06 |
20140329903 | TREATMENT OF NEURODEGENERATIVE DISEASES - The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders. | 2014-11-06 |
20140329904 | INCREASING THE BIOAVAILABILITY OF HYDROXYCINNAMIC ACIDS - The present invention generally relates to the field of nutrition, health and wellness. For example, the present invention relates to hydroxycinnamic acids and their health benefits. The present invention discloses compositions that allow increasing the bioavailability and/or bioefficacy of hydroxycinnamic acids. According to the invention, this can be achieved by co-administering at least one glycoside conjugate of a flavonoid with hydroxycinnamic acids. | 2014-11-06 |
20140329905 | HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER - The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an autophagy-related gene 4D (ATG4D) product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor. Moreover, The present invention relates to a method of predicting the risk of recurrence and/or progression of a cancer in an subject treated by cancer therapy, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an ATG4D product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) predicting the risk of recurrence and/or progression of a cancer treated by cancer therapy. The present invention also relates to a device for identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor, a kit adapted to carry out the method of the present invention. Finally, the invention relates to 2-(4-butoxyphenyl)-N-hydroxyacetamide (bufexamac) for use in treating cancer in a subject, wherein said bufexamac is to be applied in a co-treatment with cancer therapy. | 2014-11-06 |
20140329906 | THERMOGELLING ANAESTHETIC COMPOSITIONS - The present invention relates to a thermogelling pharmaceutical composition comprising local anaesthetics in base form and which is suitable for topical administration. The compositions further comprise a polyoxyethylene castor oil and one or more surfactants to obtain thermogelling characteristics. | 2014-11-06 |
20140329907 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS - Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds. | 2014-11-06 |
20140329908 | Method For The Treatment of Dravet Syndrome - A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day. | 2014-11-06 |
20140329909 | SMALL MOLECULE XANTHINE OXIDASE INHIBITORS AND METHODS OF USE - Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia. | 2014-11-06 |
20140329910 | Cooling Agent and TRPM8 Activator - Provided are a cooling agent having an excellent TRPM8 activating action, a TRPM8 activator, a method for imparting cooling sensation, and a novel compound useful for imparting cooling sensation. Disclosed is a cooling agent comprising, as an active ingredient, a compound represented by the following formula (1): | 2014-11-06 |
20140329911 | PREDICTIVE MARKER OF DNMT1 INHIBITOR THERAPEUTIC EFFICACY AND METHODS OF USING THE MARKER - Provided herein are methods for predicting efficacy of a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor treatment in a subject having a cancer, methods of identifying a subject having a cancer that is more likely to respond to a DNMT1 inhibitor treatment, and methods of selecting a treatment for a subject having a cancer that include determining a level of SOX9 in a sample containing cells from a subject having a cancer. Also provided are methods of treating a subject having a cancer that include selectively administering a DNMT1 inhibitor to a subject having cancer determined to have an elevated level of SOX9 in a sample containing cells from the subject compared to a reference level. Also provided are antibodies and antigen-binding antibody fragments that specifically bind to SOX9, and nucleic acid sequences that contain at least 10 nucleotides complementary to a contiguous sequence present in a SOX9 nucleic acid for use in these methods. | 2014-11-06 |
20140329912 | CONTRACEPTIVE COMPOSITIONS AND METHODS OF CONTRACEPTION - Compositions and methods for contraception are disclosed that use 1-bromopropane. | 2014-11-06 |
20140329913 | NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION - Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles. In the preferred embodiment, the molecular weight of the emulsifiers is less than 1500, 1300, 1200, 1000, 800, 600, or 500 amu. Preferred emulsifiers include cholic acid sodium salt, dioctyl sulfosuccinate sodium, hexadecyltrimethyl ammonium bromide, saponin, TWEEN® 20, TWEEN® 80, and sugar esters. The surface altering materials are present in an amount effective to make the surface charge of the particles neutral or essentially neutral when the one or more emulsifiers are charged. The emulsifiers have an emulsification capacity of at least about 50%, preferably at least 55, 60, 65, 70, 75, 80, 85, 90, or 95%. | 2014-11-06 |
20140329914 | Amphiphilic Peptides for Thoracic Air Leakage Occlusion - Provided are compounds and methods useful for sealing air leaks in the thoracic cavity. Compounds and compositions of the invention comprise certain amphiphilic peptides, 8-200 amino acid residues long, that self-assemble spontaneously to form a gel in the presence of physiological pH and/or in the presence of a cation. In one embodiment, the peptide comprises a repeated sequence arginine-alanine-aspartic acid-alanine (RADA). Methods of the invention include a method of occluding a pulmonary air leak in a subject, comprising applying a compound of the invention to the site of a pulmonary air leak. The compounds and methods of the invention can be combined with other agents useful to treat cancer, inflammation, or infection. | 2014-11-06 |
20140329915 | HYDROGEL ADAPTED FOR TREATMENT OF ACUTE DERMAL WOUNDS - The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods. | 2014-11-06 |
20140329916 | MICROORGANISMS AND METHODS FOR ENHANCING THE AVAILABILITY OF REDUCING EQUIVALENTS IN THE PRESENCE OF METHANOL, AND FOR PRODUCING ADIPATE, 6-AMINOCAPROATE, HEXAMETHYLENEDIAMINE OR CAPROLACTAM RELATED THERETO - Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. Also provided herein are methods for using such an organism to produce adipate, 6-aminocaproate, hexamethylenediamine or caprolactam. | 2014-11-06 |
20140329917 | APPARATUS, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS - Apparatus, systems and methods are provided for the identification of various objects, particularly circulating tumor cells. In one aspect the system includes, but is not limited to, a scanning system, an image storage system, and an analysis system. The analysis system preferably identifies desired objects, such as complete cells, based on various criteria, which may include cell nuclear area or volume, CD-45 negative status, and cytokeratine positive status. Preferably included is a slide for containing the cells during the imaging step, the well including a planar bottom surface, a border at the periphery of the well defining sides for the well, the border being adjacent the bottom surface of the well and providing a fluidic seal there between. The invention herein provides for a single imaging well, providing for substantially a monolayer of objects, e.g., cells. | 2014-11-06 |
20140329918 | SPRAYHEAD FOR A SPRAY DEVICE - A sprayhead ( | 2014-11-06 |
20140329919 | POROUS INORGANIC/ORGANIC HYBRID MATERIALS WITH ORDERED DOMAINS FOR CHROMATOGRAPHIC SEPARATIONS AND PROCESSES FOR THEIR PREPARATION - Porous hybrid inorganic/organic materials comprising ordered domains are disclosed. Methods of making the materials and use of the materials for chromatographic are also disclosed. | 2014-11-06 |
20140329920 | POLYCARBONATE-SILOXANE COPOLYMER FLAME RETARDED WITH A SILICONE BASED CORE SHELL MODIFIER - Disclosed herein are compositions including a polycarbonate-siloxane copolymer and a silicone-based graft copolymer. The compositions may include one or more additional polymers, such as a bisphenol-A polycarbonate. The compositions may include additional components, such as anti-drip agents, and/or flame retardant salt additives. Also disclosed herein are articles including the compositions, methods of using the compositions, and processes for preparing the compositions. | 2014-11-06 |
20140329921 | PROCESS FOR PRODUCING HIGH MOLECULAR WEIGHT POLYETHYLENE - In a process for producing polyethylene, ethylene is contacted under polymerization conditions with a slurry of a catalyst composition comprising a particulate support and a Group 4 metal complex of a phenolate ether ligand carried by the support and present in an amount so as to provide about 0.1 to about 35 μιηo | 2014-11-06 |
20140329922 | Superinsulation with Nanopores - This invention relates to the field of thermal insulation. In particular, the invention describes superinsulation articles having a desired porosity, reduced pore size and cost-effective methods for manufacturing such articles. In one aspect of the present invention, the article may comprise a material system with at least about 20% porosity. In a further aspect of the invention, an article may comprise greater than about 25% of nanopores having a pore size no greater than about 1500 nanometers in its shortest axis. | 2014-11-06 |
20140329923 | POLYURETHANE FOAM - A method of making a polyurethane foam from a mixture of isocyanate modified polyol and foam-forming ingredients, wherein the isocyanate modified polyol is made by reacting at least one polyol with at least one multifunctional isocyanate, wherein the isocyanate modified polyol is a non-foamed polyol polymer having available OH groups, wherein the foam forming ingredients comprise at least a multifunctional isocyanate and a foaming agent, preferably water, and characterised in that (i) the at least one polyol from which the isocyanate modified polyol is made comprises at least one lipid-based polyol which has undergone reaction with the isocyanate in the presence of a PU gelation catalyst, and/or (ii) the isocyanate modified polyol is mixed with a lipid-based polyol prior to, or at the same time as, foaming. | 2014-11-06 |
20140329924 | NEW POLYMERS DERIVED FROM RENEWABLY RESOURCED LYSINOL - Disclosed are salt compositions of lysinol and dicarboxylic acids; and lysinol derived polymers including polyamide, polyimide, polyurea, cross-linked polyurea comprising urethane linkages, polyurea foams, cross-linked polyurea foams, and lysinol-epoxy thermoset. | 2014-11-06 |
20140329925 | PHOSPHOROUS BASED POLYADDITION / POLYURETHANE-UREA POLYOLS - Embodiments of the invention include a polymer polyol dispersions. The polymer dispersions include a reaction product of a reaction system, where the reaction system includes: at least one polyol, at least one phosphorus based flame retardant having at least one active hydrogen attached to a nitrogen or oxygen atom, at least one of a co-reactant having an equivalent weight of up to 400 and at least one active hydrogen attached to a nitrogen or oxygen atom, at least one catalyst, and at least one polyisocyanate. | 2014-11-06 |
20140329926 | CURABLE RESIN COMPOSITION - An object of the present invention is to provide a curable resin composition capable of being quickly cured at a low temperature by irradiation of an active energy ray such as light and having excellent storage stability, and a curing method. Furthermore, in the curable resin composition of the present invention, which uses a component (D) in combination, the active energy ray curability is more improved. Provided is a curable composition containing components (A) to (C) described below:
| 2014-11-06 |
20140329927 | PHOTOCURABLE ADHESIVE COMPOSITION AND DISPLAY DEVICE COMPRISING SAME - The present invention relates to a photocurable adhesive composition. The photocurable adhesive composition comprises a urethane(meth)acrylate resin, a functional-group-containing polybutadiene, a photocurable monomer and a photoinitiator; and the functional group is either an epoxy group or a hydroxyl group. The photocurable adhesive composition ensures good outdoor readability, has outstanding adhesive properties, and impact strength and optical transparency, and minimizes the phenomenon whereby substantial contraction occurs during photocuring, and thus can be suitably used for a display. | 2014-11-06 |
20140329928 | PHOTOACTIVATED, PRECIOUS METAL CATALYSTS IN CONDENSATION-CURE SILICONE SYSTEMS - Photoactivated, precious metal catalysts in combination with condensation-cure silicone systems are described. Curable compositions including hydroxyl-functional polyorganosiloxanes, hydride-functional silanes, and a catalyst comprising a precious metal complexed with an actinic-radiation-displaceable ligand are described. Methods of curing such compositions and the resulting cured compositions are also discussed. | 2014-11-06 |
20140329929 | DENTAL MATERIALS BASED ON MONOMERS HAVING DEBONDING-ON-DEMAND PROPERTIES - The invention relates to a dental restorative material which comprises a thermolabile or photolabile polymerizable compound of Formula I: | 2014-11-06 |
20140329930 | RUBBER COMPOSITION AND PNEUMATIC TIRE - Provided are a rubber composition achieving balanced improvements in fuel economy, wet-grip performance, abrasion resistance, and handling stability, and a pneumatic tire including the composition. The rubber composition includes a rubber component including at least 95% by mass of conjugated diene polymers having a Tg of −75-0° C. and a Mw of 1.5×10 | 2014-11-06 |
20140329931 | RUBBER COMPOSITION AND PNEUMATIC TIRE - Provided are a rubber composition improving wet-grip performance and its temperature dependence while ensuring good fuel economy, and a pneumatic tire including the composition. The composition includes, per 100% by mass of a rubber component: 5-55% by mass of an aromatic vinyl compound/conjugated diene compound copolymer (A) having an aromatic vinyl compound content of at least 5% by mass but less than 15% by mass and a vinyl bond content in a conjugated diene compound moiety of 10-70 mol %; and 5-75% by mass of an aromatic vinyl compound/conjugated diene compound copolymer (B) having an aromatic vinyl compound content of at least 15% by mass but less than 30% by mass and a vinyl bond content in a conjugated diene compound moiety of 10-70 mol %, and also includes, per 100 parts by mass of the rubber component, 10-150 parts by mass of a silica having a N | 2014-11-06 |
20140329932 | POLYMER PARTICLES - The present invention relates to a method of preparing an aqueous dispersion of polymer encapsulated particulate material, the method comprising: providing a dispersion of the particulate material in a continuous aqueous phase, the dispersion comprising ethylenically unsaturated monomer and a stabiliser for the particulate material; and polymerising the ethylenically unsaturated monomer by non-living free radical polymerisation to form polymer that encapsulates the particulate material, thereby providing the aqueous dispersion of polymer encapsulated particulate material; wherein polymerisation of the ethylenically unsaturated monomer comprises: (a) polymerising a monomer composition that includes ionisable ethylenically unsaturated monomer so as to form a base responsive water swellable non-living polymer layer that encapsulates the particulate material; and (b) polymerising a monomer composition that includes non-ionisable ethylenically unsaturated monomer so as to form an extensible, water and base permeable non-living polymer layer that encapsulates the base responsive water swellable polymer layer. | 2014-11-06 |